secwatch.observer — SEC 8-K summary
======================================

Issuer:     Senti Biosciences, Inc. (SNTI)
CIK:        0001854270
Form:       8-K
Filed at:   2025-04-28T23:59:59+00:00
Accession:  0001854270-25-000046
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 8.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SENTI-202 Phase 1 shows 5/7 ORR in R/R AML; RP2D set; cash $33.8M at Q1 2025
----------------------------------------------------------------------------

- 5 of 7 evaluable R/R AML patients achieved ORR (3 CR, 1 CRh, 1 MLFS); all cCR patients MRD-negative.
- No dose-limiting toxicities; preliminary RP2D set at 1.5x10^9 CAR NK cells Days 0,7,14 per 28-day cycle.
- Longest ongoing response >8 months; 3 patients received bone marrow transplant after SENTI-202.
- Q1 2025 preliminary: cash $33.8M, net loss $14.1M ($1.41/share); R&D $9.3M, G&A $7.1M.
- SENTI-301A/SN301A HCC trial enrollment stopped due to dose-limiting toxicities; evaluating next steps.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1854270/000185427025000046/0001854270-25-000046-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1854270/000185427025000046/snti-20250428.htm
  HTML page:      https://secwatch.observer/filing/0001854270-25-000046

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer